ReST Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for RST-101 for the Early Treatment of Post-Traumatic Stress Disorder (PTSD)

IND Acceptance Enables Initiation of First-in-Human Clinical Trial for Novel Early Intervention Approach to PTSD ReST Therapeutics, a clinical-stage biopharmaceutical company focused on developing...